The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity. The present invention relates to novel compounds that modulate dopamine D2 receptors. In particular, compounds of the present invention show functional selectivity at the dopamine D2 receptors and exhibit selectivity downstream of the D2 receptors, on the 0- arrestin pathway and/or on the cAMP pathway.
本发明涉及新型
多巴胺D2受体
配体。该发明进一步涉及功能偏向的
多巴胺D2受体
配体以及利用这些化合物治疗或预防与
多巴胺活性失调相关的中枢神经系统和全身性疾病。本发明涉及调节
多巴胺D2受体的新型化合物。具体而言,本发明的化合物在
多巴胺D2受体上显示功能选择性,并在D2受体下游、0-阿雷斯汀途径和/或c
AMP途径上表现出选择性。